Chronic rhinosinusitis (CRS) is among the most prevalent chronic medical conditions globally. A survey of Canadian households reported the prevalence of CRS to be 5%. CRS is a clinical syndrome defined by persistent symptomatic inflammation of the mucosa in the nasal cavities and sinuses. A common subtype of CRS is CRS with nasal polyps (CRSwNP), which is identified through endoscopy or imaging
Switching biologics for CRSwNP is frequent in Canadian rhinology; the most common switch is from mepolizumab to dupilumab, with inadequate CRSwNP control driving the switch.
For chronic rhinosinusitis with nasal polyps (CRSwNP), with or without asthma, without other underlying systemic disease factors, steroid-eluting stents may not add benefit over steroid rinses.
How do the clinical effects and response times of dupilumab, omalizumab, and mepolizumab compare when treating patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP)?
What can be learned from otolaryngologists’ experiences in prescribing biologics for patients with chronic rhinosinusitis with nasal polyposis (CRSwNP), including prescribing practices, patient factors guiding prescriber decisions, and physician
Biologics represent a breakthrough for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). But with high non-response rates and other unresolved issues, researchers are exploring how best to put these therapies to work, panelists said in a session at the Triological Society Combined Sections Meeting.
LDMs provided favorable outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Multiple therapeutic options may be effective for treating mild pediatric OSA including observation, management with anti-inflammatory medications, and surgery.
Olfaction can be improved by sinus surgery in about every second chronic rhinosinusitis (CRS) patient.
Aspirin desensitization is indicated for the treatment of CRSwNP in AERD following revision ESS.